Record SaleOn May 27, Retrophin announced the sale of the Pediatric Rare Disease Priority Review Voucher mentioned on Covestor to Sanofi (SNY) for $245 million. The sales price was the highest on record for a priority review voucher and more than double the accounting value of the voucher. The windfall offers a significant additional boost to Retrophin’s balance sheet.
Exiting FXCMIn May, Cable Car closed its short position in foreign exchange broker FXCM. While the market value has approached, but not quite reached, a reasonable estimate of the remaining equity value, shares have continued to exhibit extreme volatility upon the announcement of asset dispositions and other news. While it is possible shares will ultimately receive little or no recovery, they currently exhibit option value dependent upon the future performance of the business. While sustained improvement remains unlikely, FXCM shares may present better valuation opportunities in the future.
The post Retrophin's record asset sales enhance outlook appeared first on Smarter Investing Covestor Ltd. is a registered investment advisor. Covestor licenses investment strategies from its Model Managers to establish investment models. The commentary here is provided as general and impersonal information and should not be construed as recommendations or advice. Information from Model Managers and third-party sources deemed to be reliable but not guaranteed. Past performance is no guarantee of future results. Transaction histories for Covestor models available upon request. Additional important disclosures available at http://site.covestor.com/help/disclosures. For information about Covestor and its services, go to http://covestor.com or contact Covestor Client Services at (866) 825-3005, x703.